3D-cardiac-PET: A recommendable clinical alternative to 2D-cardiac-PET

Clinical Positron Imaging (Netherlands)

Volumn 2, Issue 4, 1999, Pages 191-196

  Brink, Ingo ^a   Schumacher, Thilmann ^a   Talazko, Jochen ^c   Reuland, Peter ^a   Mix, Michael ^a   Schindler, Thomas ^b   Moser, Ernst A ^a   Nitzsche, Egbert U ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Karlsruhe General Hospital   (Germany)

Author keywords

2D Mode; 3D Mode; Cardiac Positron Emission Tomography (PET); Fluorine 18 fluorodeoxyglucose (18F FDG)

Indexed keywords

EID: 33750663798     PISSN: 10950397     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1095-0397(99)00027-8     Document Type: Article

References (30)

1. R.O Bonow The hibernating myocardium implications for management of congestive heart failure Am. J. Card. 75 1995 17A 25A
2. M.F DiCarli F Asgarzadie H.R Schelbert Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy Circulation 92 1995 3436 3444
3. M.F DiCarli J Davidson R Little Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction Am. J. Cardiol. 73 1994 527 533
4. S.R Bergmann Cardiac positron emission tomography Semin. Nucl. Med. 28 1998 320 340
5. T Marwick W MacIntyre A Lafont J Nemec E Salcedo Metabolic responses of hibernating and infarcted myocardium to revascularization a follow-up study of regional perfusion, function, and metabolism Circulation 85 1992 1347 1353
6. R.C Brunken M Schwaiger M Grover-McKay M.E Phelps J Tillisch H.R Schelbert PET detection of viable tissue metabolic activity in myocardial segments with persistent thallium perfusion defects J. Am. Coll. Cardiol. 10 1987 557 567
7. G.D Dreyfus D Duboc A Blasco Myocardial viability assessment in ischemic cardiomyopathy benefits of coronary revascularization Ann. Thorac. Surg. 57 1994 1402 1407
8. H.R Schelbert Metabolic imaging to assess myocardial viability J. Nucl. Med. 35 suppl 1994 8S 14S
9. D.L Bailey 3D acquisition and reconstruction in positron emission tomography Ann. Nucl. Med. 6 1992 123 130
10. P.D Cutler M Xu Strategies to improve 3D whole-body PET image reconstruction Phys. Med. Biol. 41 1996 1453 1467
11. D.L Bailey M.P Miller T.J Spinks Experience with fully 3D PET and implications for future high-resolution 3D tomographs Phys. Med. Biol. 43 1998 777 786
12. M Dahlbom L Eriksson G Rosenqvist C Bohm A study of possibility of using multi-slice PET systems for 3D imaging IEEE Trans. Nucl. Sci. 36 1989 1066 1071
13. R.D Badawi 3D-mode acquisition in clinical PET [editorial] Nucl. Med. Commun. 18 1997 801 804
14. S.R Cherry M Dahlboom E.J Hoffmann 3D PET using a conventional multislice tomograph without septa J. Comput. Assist. Tomogr. 15 1991 655 668
15. S.R Cherry S.R Meikle E.J Hoffmann Correction and characterization of scattered events in three-dimensional PET using scanners with retractable septa J. Nucl. Med. 34 1993 671 678
16. J.Z.J Doll H Trojan M.E Bellemann L.E Adam U Haberkorn G Brix Optimization of PET image quality by means of 3D data acquisition and iterative image reconstruction Nuklearmedizin 37 1998 62 67
17. V Sossi M.W Stazyk P.E Kinahan T.J Ruth Basal ganglia studies with 3D acquisition and 2D reconstruction on a retractable septa PET scanner J. Comput. Assist. Tomogr. 18 1994 1004 1009
18. H.J Kretschmann H Vogt T Schutz Three-dimensional reconstruction in neuroanatomy Radiologe 31 1991 481 488
19. P.K Marsden R.D Badawi J.C.H Wong M.N Maisey Validation of 3D positron emission tomography (PET) for cardiac scanning in young children Nucl. Med. Commun. 17 1996 283
20. K Hamacher H.H Coenen G Stöcklin Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-D-glucose using aminopolyether supported nucleophilic substitution J. Nucl. Med. 27 1986 235 238
21. R.J Gropler Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose J. Nucl. Cardiol. 1 1994 S4 S14
22. S.R Bergmann Cardiac positron emission tomography Semin. Nucl. Med. 28 1998 320 340
23. Y Choi R.C Brunken R.A Hawkins Factors affecting myocardial 2-[F-18]fluoro-2-deoxy- d -glucose uptake in positron emission tomography studies of normal humans Eur. J. Nucl. Med. 20 1993 308 318
24. J.A Wisneski E.W Gertz R.A Neese L.D Gruenke D.L Morris J.C Craig Metabolic fate of extracted glucose in normal human myocardium J. Clin. Invest. 76 1985 1819 1827
25. J Krivokapich S.C Huang M.E Phelps Estimation of rabbit myocardial metabolic rate for glucose using fluorodeoxyglucose Am. J. Physiol. 243 1982 H884 H895
26. H Kuwabara A Gjedde Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate J. Nucl. Med. 32 1991 692 698
27. H Kuwabara A.C Evans A Gjedde Michaelis-Menten constraints improved cerebral glucose metabolism and regional lumped constant measurements with [18F]fluorodeoxyglucose J. Cereb. Blood Flow Metab. 10 1990 180 189
28. R.J Gropler B.A Siegel K.J Lee Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans J. Nucl. Med. 31 1990 1749 1756
29. J Doll J Zaers H Trojan Optimization of PET image quality by means of 3D data acquisition and iterative image reconstruction Nuklearmedizin 37 1998 62 67
30. L Jordan S Mattsson B Nosslin Effective dose from radiopharmaceuticals Eur. J. Nucl. Med. 19 1992 933 938